James M McFarland
Harvard University
H-index: 28
North America-United States
Top articles of James M McFarland
Defining the landscape of cancer vulnerabilities that are engendered by germline genetic variation
2023/6/1
Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias
Nature Cancer
2023/5
Dissecting mechanisms underlying FOXR2-mediated gliomagenesis in diffuse midline gliomas
Cancer Research
2023/4/4
Rapid label-free imaging-based evaluation of cancer dependencies in zero-passage primary cells
Cancer Research
2023/4/4
TTX-810 is a highly selective novel MCL1 inhibitor with optimized in vivo clearance showing robust efficacy in preclinical solid and hematological tumor models with no effects …
2023/4/4
ANJ810 is a novel highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models
2023/3/3
A ubiquitination cascade regulating the integrated stress response and survival in carcinomas
Cancer discovery
2023/3/1
Partial gene suppression improves identification of cancer vulnerabilities when CRISPR-Cas9 knockout is pan-lethal
Genome Biology
2023/8/23
Brenton R Paolella
H-Index: 11
James M Mcfarland
H-Index: 16
Francisca Vazquez
H-Index: 38
Aviad Tsherniak
H-Index: 36
DIPG-20. DELINEATING MEDIATORS OF ONCOGENESIS IN FOXR2-EXPRESSING DIFFUSE MIDLINE GLIOMAS
Neuro-Oncology
2023/6/1
Phosphate dysregulation via the XPR1–KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer
Nature cancer
2022/6
Sparse dictionary learning recovers pleiotropy from human cell fitness screens
Cell systems
2022/4/20
Joshua Pan
H-Index: 9
Francisca Vazquez
H-Index: 38
Aviad Tsherniak
H-Index: 36
Marinka Zitnik
H-Index: 25
James M Mcfarland
H-Index: 16
Pan-ERBB kinase inhibition augments CDK4/6 inhibitor efficacy in oesophageal squamous cell carcinoma
Gut
2022/4/1
Germline variation contributes to false negatives in CRISPR-based experiments with varying burden across ancestries
bioRxiv
2022/11/19
Rapid prediction of drug responsiveness
2022/10/27
FOXR2 is an epigenetically regulated pan-cancer oncogene that activates ETS transcriptional circuits
Cancer research
2022/9/2
Computational estimation of quality and clinical relevance of cancer cell lines
2022/7
Phosphate dysregulation as a novel therapeutic strategy in ovarian and uterine cancers
Cancer Research
2022/6/15
Rapidly evaluating cancer dependencies by label-free imaging of zero-passage primary cells
Cancer Research
2022/6/15
Systematic methods to identify cancer vulnerabilities from genome-wide loss-of-function screens: An interactive framework for target discovery
Cancer Research
2022/6/15
Ancestry bias in CRISPR guide design impedes discovery of genetic dependencies
Cancer Research
2022/6/15
